Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCell recipient-site preparation study in vitiligo and piebaldism
NL-OMON42082Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2015
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Randomised, open-label trial of ReNovaCell in Segmental vitiligo (SV) and Piebaldism (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Objective degree of repigmentation. Started May 2015; status: active, not recruiting.
02
Drugs
ReNovaCell
03
Conditions
Segmental vitiligo (SV)Piebaldism
Beyond the preview
Go deeper on NL-OMON42082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42082.